Primidone is not technically a barbiturate, but it’s closely related to one. Chemically, it’s classified as a deoxybarbiturate, meaning its structure is nearly identical to the barbiturate phenobarbital with one key difference: it lacks the acidic properties that define true barbiturates. That distinction matters for how the drug is regulated, how it behaves in your body, and what risks it carries.
How Primidone Relates to Barbiturates
Primidone was first identified as having anti-seizure activity in 1949, and it was developed as an analog of phenobarbital. The two molecules are so similar that your liver actually converts a portion of primidone into phenobarbital after you take it. This means that when you’re on primidone, phenobarbital (a true barbiturate) is circulating in your bloodstream as an active metabolite.
Your body also converts primidone into a second active compound called phenylethylmalonamide, or PEMA. So a single dose of primidone effectively becomes three active substances: the parent drug itself, PEMA, and phenobarbital. Each contributes to the drug’s overall effect, though phenobarbital is responsible for a significant share of primidone’s anti-seizure activity.
The FDA’s own labeling for Mysoline (the brand name for primidone) notes that the drug “possesses no acidic properties, in contrast to its barbiturate analog.” That single chemical difference is what separates primidone from the barbiturate class in a strict pharmacological sense.
Why the Distinction Matters for Regulation
The practical difference between being a barbiturate and being a deoxybarbiturate shows up clearly in how the U.S. government treats these drugs. Phenobarbital is listed as a Schedule IV controlled substance by the DEA, meaning prescriptions are tracked and refills are limited. Primidone is not on the DEA’s controlled substances list at all. You still need a prescription, but it doesn’t carry the same legal restrictions around dispensing and refills that phenobarbital does.
This can be confusing, since taking primidone means your body is producing phenobarbital. If you’re subject to drug testing, primidone use will cause a positive result for barbiturates. That’s not a false positive. Your body is genuinely producing a barbiturate from the medication.
What Primidone Is Used For
Primidone is FDA-approved as an anticonvulsant for controlling seizures in epilepsy, either alone or alongside other seizure medications. It works in the brain to reduce the abnormal electrical activity that triggers convulsions.
Beyond epilepsy, primidone is widely prescribed off-label for essential tremor, a condition that causes involuntary shaking, most commonly in the hands. It’s considered one of the first-line treatments for essential tremor alongside beta-blockers like propranolol. Many people with essential tremor who don’t respond well to beta-blockers find relief with primidone, and vice versa.
How It Moves Through Your Body
Primidone itself is cleared relatively quickly, with a half-life of roughly 3 to 12 hours depending on the individual. PEMA sticks around longer, with a half-life of about 20 hours. Phenobarbital, the barbiturate metabolite, has a much longer half-life, typically 2 to 5 days. This means the barbiturate your body produces from primidone lingers in your system far longer than the parent drug does.
That long phenobarbital half-life is part of why stopping primidone abruptly can be dangerous. The barbiturate metabolite builds up in your system over weeks of treatment, and your brain adapts to its presence. Sudden withdrawal can trigger seizures even in people who don’t have epilepsy. Tapering off gradually is essential.
Side Effects and Barbiturate-Like Risks
Because primidone generates a barbiturate in your body, many of its side effects overlap with what you’d expect from phenobarbital. Drowsiness, dizziness, and loss of coordination are common, especially when first starting the medication or increasing the dose. Nausea and fatigue are also typical early on, though they often improve as your body adjusts over the first few weeks.
Primidone also carries the same dependency risk associated with barbiturates, precisely because phenobarbital accumulates during treatment. Tolerance can develop over time, and the drug has sedative properties that become more pronounced at higher doses. Alcohol amplifies these effects significantly and should be avoided.
The cognitive side effects can be meaningful too. Some people notice slowed thinking, difficulty concentrating, or memory issues, particularly at higher doses. These effects tend to be dose-dependent, so working with a lower effective dose can help minimize them.
The Bottom Line on Classification
Primidone occupies an unusual middle ground. It is not a barbiturate by strict chemical definition, and it’s not regulated as one. But it is converted into a barbiturate inside your body, produces barbiturate-like effects, triggers positive barbiturate drug screens, and carries barbiturate-associated risks including sedation, tolerance, and dangerous withdrawal. For practical purposes, anyone taking primidone should understand that they are, in effect, also taking a low dose of phenobarbital.